USFDA classifies Biocon Biologics’ Biocon Park in Bengaluru as VAI
The inspection scope had included six separate Biologics manufacturing units comprising of four Drug Substance and two Drug Product manufacturing plants
The inspection scope had included six separate Biologics manufacturing units comprising of four Drug Substance and two Drug Product manufacturing plants
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Hospital business revenues increase 13.9% to Rs. 1,655 crore
This product will be manufactured at Lupin’s Nagpur facility in India
The centre is equipped with the most modern tools and provides an environment soothing for all professionals and patients
The company uses iPS cells to develop treatments for diseases relating to the kidney
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Subscribe To Our Newsletter & Stay Updated